Wolfgang Marguerre donates €250,000 to University Hospital Heidelberg to support innovation in medical training


Octapharma AG Chairman Wolfgang Marguerre has donated €250,000 to University Hospital Heidelberg’s oral and maxillofacial surgery clinic to support innovation in medical training.


The clinic’s 26 doctors treat 30,000 patients a year carrying out oral and maxillofacial surgery including cleft lip and palate orthognathic surgery and craniofacial surgery.  The University Hospital trains almost 3,000 medical and dentistry students a year.


Wolfgang Marguerre's donation will be used by the clinic to purchase a state-of-the-art audio-visual system for training and further education purposes. The digital operating room technology displays, interacts, streams, records and enhances medical images and videos.


The system provides direct web-access to live streams, digital recordings and screenshots. Data can be shared instantly with colleagues and communicated via web-based conferencing.


Professor Dr. J. Hoffmann said, “This is a real innovation for us; we will be one of the only centres in Germany which is equipped with this type of technology, supporting post graduate education for doctors, dentists and cranio facial surgeons internationally. In addition to medical students this technology can also be used to help patients and parents understand procedures. We are delighted that Mr. Marguerre is supporting medical training and innovation for the doctors of the world who are trained in Heidelberg, and of course the patients who will benefit from this technology.”


About Octapharma


Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein product manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell-lines. Octapharma’s revenue forecast for 2015 is €1.5 billion.


Octapharma has 48 subsidiaries and representative offices and employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the therapeutic areas of Haematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. 


Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.


For more information visit